Efficacy and Safety of Probiotics for the Treatment of Alzheimer's Disease, Mild Cognitive Impairment, and Parkinson's Disease: A Systematic Review and Meta-Analysis
BackgroundAlzheimer's disease (AD) and Parkinson's disease (PD) are two of the most common neurodegenerative diseases, and mild cognitive impairment (MCI) is considered a prodromal stage of clinical AD. Animal studies have shown that probiotics can improve cognitive function and mitigate i...
Main Authors: | Shuai Xiang, Jin-Long Ji, Sha Li, Xi-Peng Cao, Wei Xu, Lan Tan, Chen-Chen Tan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-02-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2022.730036/full |
Similar Items
-
Probiotics for Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Meta-Analysis
by: Guangsu Zhu, et al.
Published: (2021-07-01) -
Ketogenic interventions in mild cognitive impairment, Alzheimer's disease, and Parkinson's disease: A systematic review and critical appraisal
by: Jeffrey L. B. Bohnen, et al.
Published: (2023-02-01) -
Validation of the European Cross-Cultural Neuropsychological Test Battery (CNTB) for the assessment of mild cognitive impairment due to Alzheimer's disease and Parkinson's disease
by: Alfonso Delgado-Álvarez, et al.
Published: (2023-05-01) -
Associations of vitamin D receptor polymorphisms with risk of Alzheimer’s disease, Parkinson’s disease, and mild cognitive impairment: a systematic review and meta-analysis
by: Yanjun Du, et al.
Published: (2024-04-01) -
Mild Behavioral Impairment in Parkinson’s Disease: An Updated Review on the Clinical, Genetic, Neuroanatomical, and Pathophysiological Aspects
by: Efthalia Angelopoulou, et al.
Published: (2024-01-01)